Targeted therapy: Can it substitute for chemotherapy?

Breast Care

Volumn 3, Issue 4, 2008, Pages 257-261

  Schütz, Florian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Breast cancer; Epidermal growth factor receptors; Targeted therapies; Vascular epidermal growth factors

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DECISION MAKING; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; VOMITING;

EID: 51849092585     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000149816     Document Type: Review

References (27)

1. Pegram MD, Pauletti G, Slamon DJ:HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
3. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM: Randomized phase III trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274.
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy in HER2 positive breast cancer. N Engl J Med 2005;353:1673-1684.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 2005;353:1659-1672.
6. Slamon DJ, Eiermann W, Robert N: Phase III-randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94 (suppl 5).
7. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib and capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
8. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
9. Schneider BP, Miller KD: Angiogenesis of breast cancer. J Clin Oncol 2005;23:1782-1790.
10. Toi M, Hoshina S, Takayanagi T, Tominaga I: Association of vascular first endothelial growth factor expression with tumor angiogenesis and with early first relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045-1049.
11. Schuetz F, Sohn C, Schneeweiss A: Bevacizumab in the treatment of breast cancer. Breast Care 2006;2:62-63.
12. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
13. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
14. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23: 792-799.
15. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Rhoades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006;12:3124-3129.
16. Miles D, Chan A, Romieu G, Dirix LY, Cortes JA, Pivot P, Tomczak T, Taran T, Harbeck N, Steger GG: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (MBC): AVADO. J Clin Oncol 2008(suppl):abstr 1011.
17. Burstein H, Parker L, Savoie J, et al: Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002;76:S115(abstr 446).
18. Bernstein JA, Schubbert T, Kong K, Mehta RS: Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: clinical response in patients with breast cancer. J Clin Oncol 2007;24(suppl):abstr 10699.
19. Baselga J, Cameron D, Miles D, et al: Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol 2007;25, No. 188(suppl):abstr 1004.
20. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, Harris AL: bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 1999;17:545-554.
21. Clarke K, Smith K, Gullick WJ, Harris AL: Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer 2001;84:1322-1329.
22. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-2935.
23. Epstein M, Ayala R, Tchekmedyian N, et al: HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2002;76:S143(abstr 570).
24. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-1716.
25. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor epidermal growth factor receptor-blocking antibodies in vivo: A role for tumor angiogenesis. Cancer Res 2001;61:5090-5101.
26. Pegram M, Yeon C, Ku N, et al: Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004;88:S124(abstr 3039).
27. Rugo H, Dickler M, Statt J, et al: Circulating endothelial cell (CEC) and tumor cell (CTC) analysis in patients receiving bevacizumab and erlotinib for metastatic breast cancer (MBC). Breast Cancer Res Treat 2004;88:5142(abstr 3088).